New radiation strategy before brain surgery shows promise

NCT ID NCT04503772

Completed Disease control Sponsor: Centre Jean Perrin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested giving a precise, high-dose radiation treatment (stereotactic radiosurgery) to brain metastases before surgical removal. The goal was to see if this approach improves local control at 6 months. The trial enrolled 70 adults with up to 4 brain metastases from certain cancers. Participants received radiation followed by surgery within 3 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic radiosurgery (SRS)
What this could lead to: If successful, this approach could reduce the chance of brain metastases returning after surgery.
What could go wrong: This is a small, non-randomized phase 2 study, so results may not be definitive. Risks include radiation side effects and the possibility that the treatment does not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES

Contacts and locations

Locations

CHU Grenoble Alpes

Grenoble, 38700, France
Centre Hospitalier d'Annecy-Genevois

Metz-Tessy, 74370, France
Centre Jean PERRIN

Clermont-Ferrand, Puy-de-Dôme, 63800, France
Centre Léon BÉRARD

Lyon, 69373, France
Hospices Civils de Lyon

Lyon, 69002, France
Institut de Cancérologie de l'Ouest

Saint-Herblain, France
Institut de cancérologie Strasbourg Europe (ICANS)

Strasbourg, 67000, France
Institut de cancérologie de la Loire Lucien Neuwirth

Saint-Priest-en-Jarez, 42270, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.